GlassScriptPhysician profile
Gregory Paul Gex
NPI 1396715470
$499.04
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $211 · 2020: $288.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $119.94 | 2019-2020 | |
| Therapeuticsmd, INC. | $57.58 | 2019-2020 | |
| Exeltis, USA INC. | $46.95 | 2020 | |
| Amag Pharmaceuticals, INC. | $39.47 | 2019-2020 | |
| Lupin INC. | $38.60 | 2019-2020 | |
| Allergan, INC. | $37.49 | 2019 | |
| Avion Pharmaceuticals | $37.39 | 2020 | |
| Merck Sharp & Dohme LLC | $22.91 | 2019-2020 | |
| Vertical Pharmaceuticals, LLC | $20.39 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.40 | 2020 | |
| Coopersurgical, INC. | $17.53 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $15.73 | 2019 | |
| Covidien LP | $14.21 | 2020 | |
| Ethicon US, LLC | $12.45 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Gex listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.